ORMP
NASDAQ · Pharmaceuticals
Oramed Pharmaceuticals Inc
$4.74
+0.07 (+1.50%)
Financial Highlights (FY 2026)
Revenue
1.38M
Net Income
63.35M
Gross Margin
—
Profit Margin
412.3%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 0.6% | 43.8% | 43.8% |
| Operating Margin | -1,176.8% | -679.0% | 19.2% | 21.2% |
| Profit Margin | 412.3% | 3,042.4% | 17.1% | 21.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.38M | 2.02M | 32.28M | 32.90M |
| Gross Profit | — | 13.1K | 14.13M | 14.40M |
| Operating Income | -16,293,799 | -13,716,627 | 6.20M | 6.98M |
| Net Income | 63.35M | 58.29M | 5.51M | 7.09M |
| Gross Margin | — | 0.6% | 43.8% | 43.8% |
| Operating Margin | -1,176.8% | -679.0% | 19.2% | 21.2% |
| Profit Margin | 412.3% | 3,042.4% | 17.1% | 21.6% |
| Rev Growth | — | -9.5% | +15.3% | -1.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 16.15M | 14.75M |
| Total Equity | — | — | 85.85M | 90.16M |
| D/E Ratio | — | — | 0.19 | 0.16 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -14,802,607 | -14,282,160 | 8.62M | 9.08M |
| Free Cash Flow | — | — | 3.23M | 4.24M |